TheEdgeResearch
Home / Stocks / ACUS

Acusphere, Inc. (ACUS)

OTC Healthcare Drug Manufacturers - Specialty & Generic
$0.00 ▲ +0.00%
Market Cap
$49
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Beta
-0.45
52-Wk Range
0.000001-0.00001
CEO
William I. Ramage D.Phil
Country
US
Currency
USD

Acusphere, Inc. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Watertown, MA, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $49. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of -2014.6%. Its beta of -0.45 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-0.00
Price / Sales
0.00
Price / Book
0.00
EV / EBITDA
0.18
Gross margin
100.0%
Operating margin
1977.0%
Net margin
-2014.6%
Return on equity
Debt / equity
0.76
Current ratio
1.45
Dividend yield
0.0%
Payout ratio
-4.2%
Company profile
Exchange
Other OTC
Employees
50
IPO date
2003-10-08
Headquarters
Watertown, MA, US
About Acusphere, Inc.

Acusphere, Inc. is a pharmaceutical firm specializing in the creation and market launch of cardiovascular treatments. Its flagship product is Imagify (perflubutane polymer microspheres), a cardiovascular medication designed to assess myocardial perfusion and aid in the diagnosis of coronary artery disease. This drug is administered as an injectable suspension. Initially established as Polymers For Medicine, Inc., the organization rebranded as Acusphere, Inc. in March 2004. Founded in 1993, the company maintains its headquarters in Watertown, Massachusetts.

Comparable companies

Acusphere, Inc. is most often compared with the following Healthcare names:

AQSZFBBBTDVLPIRBSMCICNEPTFNXENRMRKTOMDFXTXXF
More research on ACUS
ACUS technical analysis ACUS TheEdge Score Compare against peers
Open full interactive analysis & DCF →